BIOCRYST PHARM WKN: 896047 ISIN: US09058V1035 Kürzel: BCRX Forum: Aktien Thema: Hauptdiskussion

Noch 10 Tage bis zum R&D day!

https://ir.biocryst.com/news-releases/news-release-details/biocryst-receives-positive-chmp-opinion-orladeyotm-berotralstat

Stürzt ganz schön ab.

Nachgelegt! War zu erwarten, dass es wenig revenues gab.

https://www.google.com/amp/s/seekingalpha.com/amp/news/3666251-biocryst-pharmaceuticals-eps-misses-0_09-misses-on-revenue

Bin auch gespannt, aber plane lange drin zu bleiben

Sehr schöner Verlauf heute. Morgen dann die Quartalszahlen. Ich bin sehr gespannt!

Hält sich doch ganz gut heute

Outch, gestern eingestiegen und schon fett im minus ^^

Eine der meist geshorteten Aktien auf dem Markt, warum und wo ist der Haken hier?

Morgen an alle 🤗

Nice

https://www.clinicaltrials.gov/ct2/history/NCT04330534?A=1&B=2&C=merged

Habe ich Mal von red.dit kopiert. Sehe es aber ähnlich, was die nächsten Monate angeht.

BCRX-9930 (c5-resistant/non-responder) data - has potential to be blockbuster news, and man how nice would it be for those PNH patient to finally have an adequate treatment that works. Feb 25th Q4 ER/Corp Update - not expecting much in terms of sales, however guidance on Orladeyo uptake would be nice. AAAI conference - discussing Orladeyo here... Would be nice if they can show promising testimonials from patients who stayed on the treatment from clinical trials, new conversion rates, etc. Approval of Orladeyo in Europe (in my opinion this is already a sure thing - just waiting for confirmation) New clinical trials for BCRX-9930: there are a few to be considered e.g. a brand new indication like Lupus Nephritis, however I think they will focus on PNH in kidney/liver compromised patients first. Launch of Oraldeyo in Germany -- ready to go, just waiting for that approval. Q1 ER - which will show an entire quarter of Orladeyo sales in US, and partial sales coming from Japan/Tori. To give a conservative estimate, lets say they have 200 paying patients on Orladeyo (again very conservative). at $40k per 28 days and 1 quarter being roughly 84 days, this would be 200 x $40K x 3 packs = $24MM in sales. MAJOR analyst upgrades after revenues for Orladeyo beat current estimates ($20 + range imo) - especially from Liisa Bayko (Evercore) Insider purchases, Dr. Alex Denner increasing his stake to 10% in the company (again just my opinion), Bakers make a substantial move of some sort, lots can happen in this regard.

Ich glaube an biocryst und sollte auch nur ein Teil von dem, was auf der Seite steht, eintreffen in den nächsten Jahren, sollte der Kurs nach oben gehen.